Biocon Q1 FY27 Earnings Call: Net Profit Surges 355%, Biosimilars Drive Growth Across Global Markets

What Happened ?

Biocon reported another quarter of growth led by its Biosimilars business, which continued benefiting from strong demand in North America and recent commercial launches. Generics also delivered healthy revenue growth with improving operating leverage, while the Services segment experienced temporary weakness due to lower offtake from a key biologics customer and forex hedge losses.

Management stated that the company is entering the next phase of growth, supported by an integrated global platform, expanded manufacturing capabilities and a stronger commercial portfolio across developed and emerging markets. 

key details

Strong Consolidated Financial Performance:

• Revenue from Operations increased 10% YoY.
• Total Revenue reached ₹4,391 crore.
• EBITDA grew 7% YoY.
• EBITDA margin remained stable at 21%.
• Reported Net Profit increased 355% YoY.
• R&D investment remained at 7% of revenue excluding Syngene.

Note:

• Continued investment in research and development supports Biocon’s long-term biosimilar and specialty pharmaceutical pipeline. 

Biosimilars Continue to Lead Growth:

• Biosimilars revenue increased 16% YoY to ₹2,855 crore.
• Growth was primarily driven by the North American market.
• EBITDA increased 10% YoY to ₹728 crore.
• EBITDA margin remained strong at 25%.
• Recent launches include:
  • Yesafili (bAflibercept)
  • Bosaya & Aukelso (bDenosumab)
  • Generic Liraglutide
• EMA approval for the second insulin drug product line in Malaysia doubled manufacturing capacity.

Note:

• Management expects Biosimilars growth momentum to strengthen further during the second half of FY27 as new product launches gain traction. 

Generics Business Shows Margin Expansion:

• Revenue increased 21% YoY to ₹760 crore.
• EBITDA improved to ₹56 crore from a loss in the previous year.
• EBITDA margin improved to 7%.
• Generic Liraglutide remained a major growth driver across multiple markets, including the United States.
• Lower R&D intensity and operating leverage contributed to higher profitability.

Note:

• Investments in peptides, fermentation and manufacturing are expected to support further utilization-led margin expansion. 

Services Business Faces Temporary Headwinds:

• Services revenue declined 16% YoY to ₹736 crore.
• EBITDA declined 48% YoY to ₹116 crore.
• Lower offtake from a key biologics customer affected quarterly performance.
• Forex hedge losses also impacted profitability.
• Cost optimization initiatives partially offset the decline.

Note:

• Management expects FY27 to be a transition year for the Services business, with performance improving during the second half and sustainable growth targeted from FY28 onward. 

Global Commercial Expansion:

• North America remains Biocon’s largest strategic market.
• Europe portfolio now includes:
  • 11 biosimilars
  • 8 generic medicines
• Recent launches include:
  • Evfraxy® (bDenosumab)
  • Abevmy® (bBevacizumab)
• Yesafili launched in Malaysia.
• Continued market leadership for bevacizumab in Brazil.

Note:

• Expanded regional supply networks and strategic partnerships continue strengthening Biocon’s global commercial footprint. 

Management Outlook:

Management highlighted:

• Growth momentum is expected to build progressively through FY27.
• H2 FY27 is expected to outperform H1.
• Expanded manufacturing capacity will support future launches.
• Continued focus on improving:
  • Margins
  • Free cash flow
  • Return on Capital Employed (RoCE)
• Long-term objective remains sustainable shareholder value creation.

Note:

• Management believes recent commercial launches, integrated manufacturing and improving operating leverage position the company well for its next growth phase. 

Risk Analysis

Summary:

• Although Biocon continues benefiting from global biosimilar expansion and improving profitability, future performance depends on successful commercialization of new products, customer demand, regulatory approvals and recovery in the Services business.

Key Risks:

• Regulatory approval delays in key markets.
• Pricing pressure in global biosimilars.
• Lower demand from large biologics customers.
• Foreign exchange volatility.
• Execution risks in commercialization of new launches.
• Higher R&D investments affecting near-term profitability.

Worst Case:

• If commercialization of recently launched products slows or Services business recovery is delayed, revenue growth and profitability could moderate despite continued strength in Biosimilars and Generics.

Risk Level: Medium

Conclusion

• Integrated global platform continues strengthening competitive positioning.
• Biosimilars remain the primary growth engine.
• Generics profitability is improving through operating leverage.
• Manufacturing expansion supports future product launches.
• Management expects stronger performance during H2 FY27.
• Focus remains on translating scale into stronger earnings, free cash flow and shareholder value.